Düsseldorf/Berlin, Ohio (U.S.), April 27, 2020. On April 20, Gerresheimer Group company Centor Inc. laid the foundations for a new warehouse covering 72,000 square meters. The new storage facility is being built right next to the existing one on Centor’s site in Berlin, Ohio (U.S.). This new warehouse will enable Centor to store all of its products on site, reducing the need for external storage.
“With the new warehouse, we will be able to improve the way we serve our customers and further consolidate our position on the U.S. market for prescription medicines packaging,” said Mitch Stein, Centor Plant Manager, who has been working for the company for 32 years.
Centor was founded in 1968 and has its headquarters in Perrysburg, Ohio, while its plant is based in Berlin, Ohio (U.S.). It is the leading manufacturer of plastic packaging and closures for prescribed oral medication on the U.S. retail market. Centor has been part of Gerresheimer since 2015. In the U.S., a common feature on the market for prescription medicines is the “pour-and-count” system. This means that the exact quantity of the oral medicine stated in the prescription is measured into plastic containers specifically for each individual patient. Centor boasts a strong product portfolio for this area, including the Screw-Loc and 1-Clic product lines – the top two varieties of plastic packaging in the U.S. Centor supplies regional and national drugstore chains, supermarkets, and wholesalers.
In addition to Centor in Berlin and Perrysburg (Ohio), Gerresheimer’s holdings in North America also include production sites for glass and plastic pharmaceutical containers and products in Chicago (Illinois), Peachtree (Georgia), and Vineland (Morganton and Forest Grove, New Jersey).
In light of the coronavirus pandemic, Centor has decided not to hold an official opening ceremony for safety reasons and plans to make up for this at a later date.
Gerresheimer is a leading global partner to the pharma and healthcare industry. With specialty glass and plastic products, the Company contributes to health and well-being. Gerresheimer operates worldwide and its approximately 10,000 employees manufacture products in local markets, close to its customers. With plants in Europe, the Americas, and Asia, Gerresheimer generates revenues of around EUR 1.4 billion. The comprehensive product portfolio includes pharmaceutical packaging
and products for the safe, simple administration of medicines: insulin pens, inhalers, micro pumps, prefillable syringes, injection vials, ampoules, bottles, and containers for liquid and solid medicines with closure and safety systems as well as packaging for the cosmetics industry.
02.05.2020, Gerresheimer Glas
Les informations publiées sur notre portail sont soumises au droit d´auteur et appartiennent à la société en question resp. à la source des nouvelles. Tous les droits sont réservés expressément. N´importe quel utilisateur qui accède à un tel matériel peut faire ainsi seulement pour sa propre utilisation personnelle, et l´usage d´un tel matériel est au risque unique de l´utilisateur. La redistribution ou toute autre exploitation commerciale d´un tel matériel de nouvelles est expressément interdite. Là où un tel matériel de nouvelles est fourni par un tiers, chaque utilisateur accepte d´observer et être lié par les limites spécifiques de l´utilisation s´appliquant à un tel matériel de nouvelles. Glass Global ne représente ou n´approuve pas l´exactitude ou la fiabilité d´aucune des informations citées dans les nouvelles ou pages externes auxquelles on se réfère ici.
Should the content or the design of these sites violate third parties rights or legal prescriptions, we kindly ask you to send us a respective message without invoice or cost. We guarantee that passages where the claim is considered as justified will be removed immediately, without any necessity to involve any lawyer into this issue. We will reject any claim caused by submission of a honorary note in this regard without any prior contact and confirmation of the issueby us and we reserve the right ssue counter claim ourselves because of violation of aforesaid conditions.